Literature DB >> 11937340

2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide.

Gary J Tarver1, Simon J A Grove, Kirsteen Buchanan, Anton Bom, Andrew Cooke, Samantha J Rutherford, Ming Qiang Zhang.   

Abstract

A series of secondary face modified cyclodextrins (CDs) were synthesised with the aim of constructing host molecules capable of forming host-guest complexes with neuromuscular blockers, especially with rocuronium bromide. Perfacial 2-O-substitution of gamma-CD with 4-carboxybenzyl resulted in a CD host molecule 1 that forms a 1:1 binary complex with rocuronium bromide (K(a) 6.2 x 10(5) M(-1)). The biological activities of this compound and other derivatives as reversal agents of rocuronium bromide were examined in vitro (mouse hemi-diaphragm) and in vivo (anaesthetized guinea pigs). The host molecule 1 was found to exert potent reversal activity (ED(50) 0.21 micromol/kg, iv) against rocuronium-induced neuromuscular block, and thus proved the viability of using host molecules as antidotes of a biologically active compound.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937340     DOI: 10.1016/s0968-0896(02)00026-3

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  Facile synthesis of per(6-O-tert-butyldimethylsilyl)-α-, β-, and γ-cyclodextrin as protected intermediates for the functionalization of the secondary face of the macrocycles.

Authors:  Gábor Benkovics; Milo Malanga; Giovanna Cutrone; Szabolcs Béni; Antonio Vargas-Berenguel; Juan Manuel Casas-Solvas
Journal:  Nat Protoc       Date:  2021-01-15       Impact factor: 13.491

2.  Simulation of the reversal of neuromuscular block by sequestration of the free molecules of the muscle relaxant.

Authors:  Vladimir Nigrovic; Shashi B Bhatt; Anton Amann
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-09-21       Impact factor: 2.410

3.  Anaesthetic management of a patient with myasthenia gravis for abdominal surgery using sugammadex.

Authors:  Alina Rudzka-Nowak; Mariusz Piechota
Journal:  Arch Med Sci       Date:  2011-05-17       Impact factor: 3.318

Review 4.  Sugammadex: A revolutionary drug in neuromuscular pharmacology.

Authors:  Kusha Nag; Dewan Roshan Singh; Akshaya N Shetti; Hemanth Kumar; T Sivashanmugam; S Parthasarathy
Journal:  Anesth Essays Res       Date:  2013 Sep-Dec

5.  Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent.

Authors:  Mark Welliver; John McDonough; Nicholas Kalynych; Robert Redfern
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

6.  Selective reversal of muscle relaxation in general anesthesia: focus on sugammadex.

Authors:  Sorin J Brull; Mohamed Naguib
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

7.  The Strategy to Use Sugammadex to Reduce Postoperative Pulmonary Complications after da Vinci Surgery: A Retrospective Study.

Authors:  Kuang-I Cheng; Jockey Tse; Tzu-Ying Li
Journal:  J Pers Med       Date:  2022-01-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.